Simnotrelvir/ritonavir

From Wikipedia, the free encyclopedia
(Redirected from Simnotrelvir)
Jump to navigation Jump to search

Simnotrelvir/ritonavir
File:Simnotrelvir.svg
File:Ritonavir structure.svg
Chemical structures of simnotrelvir (top) and ritonavir (bottom)
Combination of
SimnotrelvirSARS-CoV-2 3CLpro inhibitor
RitonavirProtease inhibitor
Clinical data
Trade names先诺欣 (Xiannuoxin)
Pregnancy
category
  • Contraindicated (CN)
Routes of
administration		Oral
Legal status
Legal status
  • Rx in China
Identifiers
E number{{#property:P628}}
CompTox Dashboard (EPA)
  • {{#property:P3117}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
Simnotrelvir
Clinical data
Other namesSIM0417, SSD8432
Routes of
administration		Oral
Drug classSARS-CoV-2 3CLpro inhibitor
Legal status
Legal status
  • Not approved on its own
Pharmacokinetic data
Protein binding72.5%[1]
Metabolismhepatic (CYP3A)[1]
Elimination half-life3.1 h; 4.1 h with ritonavir[1]
Excretionurine (55.4%), feces (36.7%)[1]
Identifiers
  • (8S)-N-[(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-7-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxamide
PubChem CID
E number{{#property:P628}}
CompTox Dashboard (EPA)
  • {{#property:P3117}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC22H30F3N5O4S2
Molar mass549.63 g·mol−1
3D model (JSmol)
  • CC(C)(C)[C@@H](C(=O)N1CC2(C[C@H]1C(=O)N[C@@H](C[C@@H]3CCNC3=O)C#N)SCCS2)NC(=O)C(F)(F)F
  • InChI=InChI=1S/C22H30F3N5O4S2/c1-20(2,3)15(29-19(34)22(23,24)25)18(33)30-11-21(35-6-7-36-21)9-14(30)17(32)28-13(10-26)8-12-4-5-27-16(12)31/h12-15H,4-9,11H2,1-3H3,(H,27,31)(H,28,32)(H,29,34)/t12-,13-,14-,15+/m0/s1
  • Key:LQBRGTAIBBFUJJ-ZQDZILKHSA-N

Simnotrelvir/ritonavir (trade name Xiannuoxin) is a pharmaceutical drug used for the treatment of COVID-19.[2] Simnotrelvir/ritonavir is a combination drug of simnotrelvir, an inhibitor of SARS-CoV-2 3CLpro, and ritonavir,[3] a CYP3A inhibitor.

It was developed by Simcere Pharmaceutical and conditionally approved in China by the National Medical Products Administration (NMPA) in January 2023.[4] Results for the phase Ib trial are available.[5] In a phase II/III trial, it reduced the duration of symptoms by a median of 36 hours compared to placebo.[6]

See also

[edit | edit source]

References

[edit | edit source]
  1. ^ a b c d Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  2. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  3. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  4. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  5. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  6. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
[edit | edit source]
Stub icon

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "http://70.231.62.181/index.php?title=Simnotrelvir/ritonavir&oldid=19445340"